Amarin Corp Plcuk 8-K, filed Apr 17, 2023
Amarin Corp Plcuk (AMRN)
About this 8-K
Amarin Corp Plcuk filed this 8-K on April 17, 2023.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
|
||
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
|
|
|
|
Not applicable |
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code:
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading |
|
Name of each exchange |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ACTIVE/122789132.1
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Appointment of Interim CEO
On April 17, 2023, the Board of Directors (the “Board”) of Amarin Corporation plc (the “Company”) appointed Aaron Berg, current Executive Vice President, President-U.S. of the Company, as the Interim Chief Executive Officer and President of the Company and as the interim principal executive officer of the Company. Mr. Berg will continue to serve as Executive Vice President, President-U.S. in addition to his role as Interim Chief Executive Officer.
Mr. Berg, 60, joined the Company in November 2012 as Vice President, Marketing and Managed Care. He has since served in roles of increasing responsibility, including as Senior Vice President, Marketing and Sales from February 2014 until April 2018, as Senior Vice President and Chief Commercial Officer from April 2018 through July 2021, and currently as Executive Vice President, President-U.S., a position he has held since August 2021. Before joining the Company, Mr. Berg served as president and chief executive officer of Essentialis, Inc., a development stage pharmaceutical company, where he led the company’s work on triglyceride management. Prior to joining Essentialis, Mr. Berg served as vice president of marketing and sales at Kos Pharmaceuticals, where he was instrumental in driving annual revenues approaching $1 billion until the acquisition of Kos Pharmaceuticals by Abbott Laboratories in December 2006. Mr. Berg began his pharmaceutical industry career as a sales representative with Bristol-Myers Squibb, followed by various commercial positions with Schering-Plough and GlaxoSmithKline. He obtained his B.S. in Business Management, Marketing from the University of Maryland.
In connection with Mr. Berg’s becoming the Company’s Interim Chief Executive Officer and President, the Company entered into a letter agreement for the provision of Mr. Berg’s services (the “Agreement”). Pursuant to the Agreement, Mr. Berg will be paid an annual base salary of $700,000 per year, with his target bonus continuing to be 50% of his salary earned in his role as Executive Vice President, President-U.S., and the other terms of his employment to otherwise be consistent with the terms of his current employment agreement with the Company, which is filed as Exhibit 10.28 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.
There are no other arrangements or understandings between Mr. Berg and any other persons pursuant to which he was selected as an officer of the Company. There are also no family relationships between Mr. Berg and any director or executive officer of the Company and Mr. Berg has no direct or indirect material interest in any related party transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
Appointment of Director
On April 17, 2023, the Board appointed Oliver O’Connor, 61, to the Board to a term commencing on such date. In accordance with the Company’s articles of association, Mr. O’Connor will serve until the Company’s 2023 annual general meeting of shareholders, when he will be a nominee for election to the Board by a vote of the Company’s shareholders. Mr. O’Connor was also appointed to the Nominating and Corporate Governance Committee of the Board.
Mr. O’Connor will receive annual compensation for his service on the Board and any applicable committees, in each case, in accordance with the Company’s non-employee director compensation policy, the material terms of which policy, currently in effect, are disclosed under “Item 11. Executive Compensation-Director Compensation-Non-Employee Director Compensation” of Amendment No. 1 on Form 10-K/A to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the U.S. Securities and Exchange Commission on May 2, 2022. Consistent with the current members of the Board, Mr. O’Connor has declined his initial equity award under the policy while the Board is undertaking a review of the current non-employee director compensation policy. The Company expects to enter into a deed of indemnity with Mr. O’Connor, in substantially the same form entered into with the other directors of the Company.
There are no other arrangements or understandings between Mr. O’Connor and any other person pursuant to which Mr. O’Connor was selected as a director. Mr. O’Connor is not a party to any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
Item 7.01 Regulation FD Disclosure
On April 17, 2022, the Company issued a press release announcing the appointment of Mr. Berg as the Company’s Interim Chief Executive Officer and the appointment of Mr. O’Connor to the Board. A copy of the Company’s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 7.01.
ACTIVE/122789132.1
The information set forth under Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. |
|
Description |
|
||
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
ACTIVE/122789132.1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Date: April 17, 2023 |
|
|
|
Amarin Corporation plc |
||
|
|
|
|
|||
|
|
|
|
By: |
|
/s/ Tom Reilly |
|
|
|
|
|
|
Tom Reilly |
|
|
|
|
|
|
Chief Financial Officer |
ACTIVE/122789132.1
Exhibit 99.1
AMARIN NAMES AARON BERG INTERIM PRESIDENT & CHIEF EXECUTIVE OFFICER AND ADDS OLIVER O’CONNOR TO COMPANY’S BOARD OF DIRECTORS
DUBLIN, Ireland and BRIDGEWATER, N.J., April 17, 2023 – Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company’s Board of Directors has appointed Aaron Berg, currently Amarin’s Executive Vice President and President of the U.S. Business, as Interim President and Chief Executive Officer (CEO). In addition, the board has appointed Oliver O’Connor as a new independent Director of the company. Both appointments are effective immediately.
“As the board works quickly to identify a permanent CEO, we are excited to have Aaron step up to lead Amarin at this important time,” said Odysseas Kostas, M.D., and Chairman of the Board. “Aaron brings immense experience in the cardiovascular space and a strong commitment to Amarin and the value of VASCEPA® for patients worldwide. The board looks forward to working together with Aaron quickly to further optimize operations and capital allocation for the Company.”
“I am energized by this opportunity to bring my significant experience and knowledge of the Company and the cardiovascular category as we work to advance Amarin’s strategy in a thoughtful way, together,” said Aaron Berg, Interim President & CEO, Amarin. “I look forward to working with our team and the Board of Directors to focus on key priorities for the Company.”
Mr. Berg joined Amarin in November 2012 and has more than 25 years of biopharmaceutical industry experience. Mr. Berg initially served as Amarin’s Vice President, Marketing and Managed Care. He was promoted to Senior Vice President, Marketing and Sales in February 2014, and to the position of Senior Vice President and Chief Commercial Officer in April 2018. Before joining Amarin, Mr. Berg served as President and Chief Executive Officer for Essentialis, Inc., a development stage pharmaceutical company where he led the company's work on triglyceride management. Prior to joining Essentialis, Mr. Berg served as Vice President of Marketing and Sales at Kos Pharmaceuticals (Kos), where he was instrumental in driving annual revenues approaching $1 billion. Mr. Berg worked at Kos until it was acquired by Abbott Laboratories in December 2006 for $3.7 billion.
“We are also excited to welcome Oliver to the board,” Dr. Kostas said. “Oliver’s deep government and policy experience, matched with his knowledge of the global healthcare and biopharma industry, will be invaluable to Amarin as we look to thoughtfully and strategically unlock the significant value of VASCEPA outside of the U.S.”
Mr. O’Connor brings more than 30 years of experience in government and policy, pharmaceutical industry, banking and finance experience to the Amarin Board. He currently serves as CEO of the Irish Pharmaceutical Healthcare Association and as a Board Member of the Irish Medicines Verification Organisation. Earlier in his career, Mr. O’Connor served as an advisor to the Deputy Prime Minister, Minister for Enterprise, Trade and Employment and Minister for Health and Children in Ireland. With the addition of Mr. O’Connor, the Amarin Board of Directors now comprises 8 directors, including an Irish-domiciled Board member and all of whom are independent.
About Amarin
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk for patients worldwide. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world.
Forward-Looking Statements
This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of federal and other securities laws, including the Private Securities Litigation Reform Act of 1995. Such statements include beliefs about the value of VASCEPA, the future of Amarin and plans to optimize operations and capital allocation, and the contributions of Mr. Berg and Mr. O’Connor to such efforts. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including Amarin’s annual report on Form 10-K for the year ended December 31, 2022, and its other filings, including its quarterly reports on Form 10-Q and current reports on Form 8-K. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Amarin undertakes no obligation to update or revise the information contained in its forward-looking statements, whether as a result of new information, future events or circumstances or otherwise. Amarin’s forward-looking statements do not reflect the potential impact of significant transactions the company may enter into, such as mergers, acquisitions, dispositions, joint ventures or any material agreements that Amarin may enter into, amend or terminate.
Availability of Other Information About Amarin
Amarin communicates with its investors and the public using the company website (www.amarincorp.com) and the investor relations website (investor.amarincorp.com), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Amarin Contact Information
Investor Inquiries:
Lisa DeFrancesco
Amarin Corporation plc
IR@amarincorp.com
Media Inquiries:
Mark Marmur
Amarin Corporation plc
PR@amarincorp.com